The bottom line for lesion localization in breast cancer

Abstract

The development of radioisotope-independent, wire-free localization techniques for excision of non-palpable breast cancer will continue to expand rapidly within the next few years, increasing market competition. It is imperative that the introduction of these new technologies is correctly evaluated in terms of their major logistical benefits in streamlining pathways from radiology to the operating theatre and subsequent financial savings, rather than focusing upon margin re-excision rates—in which they are unlikely to advance current practice.